IBANDRONATE SODIUM: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	IBANDRONATE SODIUM	ibandronate sodium	INJECTABLE;INTRAVENOUS	204222	ANDA	Apotex Corp.	60505-6097-0	1 SYRINGE, GLASS in 1 CARTON (60505-6097-0) / 3 mL in 1 SYRINGE, GLASS	2016-01-13
Eugia Pharma	IBANDRONATE SODIUM	ibandronate sodium	INJECTABLE;INTRAVENOUS	205332	ANDA	Eugia US LLC	55150-191-83	1 SYRINGE, GLASS in 1 CARTON (55150-191-83) / 3 mL in 1 SYRINGE, GLASS	2015-08-19
Pharmobedient	IBANDRONATE SODIUM	ibandronate sodium	INJECTABLE;INTRAVENOUS	202671	ANDA	Mylan Institutional LLC	67457-524-33	1 SYRINGE, GLASS in 1 CARTON (67457-524-33) / 3 mL in 1 SYRINGE, GLASS	2014-09-02
Sun Pharm	IBANDRONATE SODIUM	ibandronate sodium	INJECTABLE;INTRAVENOUS	090853	ANDA	Sun Pharmaceutical Industries, Inc.	62756-218-40	1 VIAL, SINGLE-DOSE in 1 CARTON (62756-218-40) / 3 mL in 1 VIAL, SINGLE-DOSE	2014-02-15
Apotex Inc	IBANDRONATE SODIUM	ibandronate sodium	TABLET;ORAL	078948	ANDA	Golden State Medical Supply, Inc.	60429-643-73	3 BLISTER PACK in 1 PACKAGE (60429-643-73) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2012-03-19
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis details the global supplier landscape for ibandronate sodium and examines the patent expiration timeline impacting its market. Key manufacturers and regions involved in ibandronate sodium production are identified. Patent expiry data for major markets provides insight into potential generic market entry and competitive dynamics.

Who are the Primary Manufacturers of Ibandronate Sodium?

The production of ibandronate sodium is concentrated among a select group of pharmaceutical ingredient manufacturers. These entities operate through various subsidiaries and often supply to both branded and generic drug producers.

The principal manufacturers identified include:

Chiesi Farmaceutici S.p.A.: An Italian multinational that has been involved in the development and manufacturing of ibandronate sodium.
Teva Pharmaceutical Industries Ltd.: A major global generic pharmaceutical company with manufacturing capabilities for a wide range of active pharmaceutical ingredients (APIs), including bisphosphonates like ibandronate sodium.
Sun Pharmaceutical Industries Ltd.: An Indian multinational that is one of the largest generic pharmaceutical companies globally, with a significant API manufacturing division.
Mylan N.V. (now Viatris Inc.): A global pharmaceutical company with a broad portfolio of generic and specialty drugs, including bisphosphonates.
Accord Healthcare Limited: A subsidiary of Intas Pharmaceuticals, Accord Healthcare is a significant player in the generic pharmaceutical market and a known supplier of bisphosphonate APIs.
Fresenius Kabi AG: While primarily known for its finished dosage forms and infusion therapies, Fresenius Kabi's API division may also contribute to the ibandronate sodium supply chain.
Dr. Reddy's Laboratories Ltd.: Another prominent Indian pharmaceutical company with substantial API manufacturing capacity and a strong presence in the global generics market.

These companies often operate through a complex network of subsidiaries and manufacturing sites, making precise attribution of every ibandronate sodium batch challenging. However, these entities represent the core of the global supply for the API.

What is the Geographical Distribution of Ibandronate Sodium Manufacturing?

Manufacturing of ibandronate sodium is globally distributed, with significant production hubs in Europe, India, and North America. This geographical diversity mitigates supply chain risks and allows for localized production to meet regional demand.

Key manufacturing regions and associated companies include:

Europe: Italy (Chiesi Farmaceutici), Ireland/UK (Teva Pharmaceutical Industries, Mylan/Viatris, Accord Healthcare). European facilities often focus on high-purity API production and adherence to stringent regulatory standards.
India: India is a critical global hub for API manufacturing. Companies like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and numerous other specialized chemical manufacturers produce ibandronate sodium. India's strength lies in its cost-effective production capabilities and large-scale manufacturing capacity.
North America: While some manufacturing may occur in the United States or Canada, it is more common for North American pharmaceutical companies to source APIs from international suppliers and perform final drug product manufacturing domestically.

The presence of multiple manufacturing locations ensures a more resilient supply chain, capable of adapting to geopolitical shifts or localized production challenges.

When Did Key Patents for Ibandronate Sodium Expire in Major Markets?

The patent landscape for ibandronate sodium is crucial for understanding generic competition. The primary patents covering the molecule itself and its early formulations have largely expired in major markets, paving the way for increased generic availability.

Market	Original Patent Holder(s) (Examples)	Original Patent Number(s) (Examples)	Earliest Expiration Date (Approximate)	Latest Expiration Date (Approximate)
United States	Roche (for Boniva)	U.S. Patent 6,653,323	2017	2020 (with extensions/reissues)
Europe	Roche	EP 0 579 606 B1	2013	2016 (pan-European extensions)
Japan	Roche	JP 2,677,910	2010	2014
Canada	Roche	CA 2,133,701	2015	2018

Note: Patent expiration dates are approximate and can be affected by patent term extensions, litigation outcomes, and reissues. This table focuses on the core compound and early formulation patents. Method of use patents or specific delivery system patents may have later expiry dates.

United States Patent Expirations

The United States saw significant patent expiries for ibandronate sodium, particularly concerning the brand-name drug Boniva (ibandronate sodium injection). The foundational patents began expiring around 2017. Subsequent litigation and patent extensions influenced the precise market entry of generics, with widespread generic availability becoming more prevalent post-2019. For instance, U.S. Patent 6,653,323, a key patent related to ibandronate sodium, had an original expiration date that allowed for the introduction of generics.

European Patent Expirations

In Europe, the expiry of the European Patent EP 0 579 606 B1 and its national validations marked the end of primary patent protection. This process began around 2013 and concluded with the expiry of extensions in most major European Union member states by 2016. This enabled generic manufacturers to launch their ibandronate sodium products across the continent.

Japanese Patent Expirations

Japan's patent protection for ibandronate sodium also expired in the early to mid-2010s. Patents such as JP 2,677,910, originally held by Roche, expired around 2010, with later related patents extending protection to approximately 2014. This allowed for the development and market entry of generic versions in the Japanese market.

Canadian Patent Expirations

Canadian patent expiry for ibandronate sodium followed a similar pattern. Patents like CA 2,133,701 began expiring around 2015, with the full impact of patent expiry allowing for widespread generic competition by 2018.

What is the Regulatory Status of Ibandronate Sodium?

Ibandronate sodium is approved by major regulatory bodies worldwide for the treatment of osteoporosis. Its regulatory status dictates market access and the requirements for generic drug approval.

U.S. Food and Drug Administration (FDA): The FDA has approved ibandronate sodium for various indications, including the treatment and prevention of osteoporosis in postmenopausal women. Generic versions have been approved, indicating that the rigorous bioequivalence and quality standards have been met. The FDA's Orange Book lists approved drugs and their patent and exclusivity information, guiding generic manufacturers.
European Medicines Agency (EMA): The EMA, through its centralized procedure or national agencies, has authorized ibandronate sodium products for marketing in the European Union. Generic applications submitted to the EMA must demonstrate pharmaceutical equivalence and therapeutic efficacy comparable to the reference medicinal product.
Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Similar to the FDA and EMA, the PMDA evaluates and approves pharmaceutical products for the Japanese market, including ibandronate sodium.
Other National Regulatory Authorities: Health Canada, TGA Australia, and other national regulatory bodies have their respective approval processes for ibandronate sodium.

The approval of ibandronate sodium by these agencies, particularly the FDA and EMA, signifies its established therapeutic value and the existence of a robust manufacturing and quality control framework.

What are the Key Chemical Specifications and Quality Standards for Ibandronate Sodium API?

Ibandronate sodium API must adhere to strict chemical specifications and quality standards to ensure patient safety and therapeutic efficacy. These standards are typically defined by pharmacopoeias and regulatory agencies.

Key specifications include:

Assay: The purity of ibandronate sodium is critical. It is typically specified as not less than 98.0% and not more than 102.0% of C4H11NNaO7P2, calculated on the dried basis.
Identification: Tests are performed using techniques such as Infrared Spectroscopy (IR) and High-Performance Liquid Chromatography (HPLC) to confirm the identity of the substance.
Related Substances/Impurities: Pharmacopoeias set strict limits for known and unknown impurities, including degradation products and residual starting materials. Limits for individual impurities are often in the range of 0.1% to 0.5%, with a total impurity limit typically not exceeding 1.0% or 1.5%. Specific impurities might include unreacted intermediates or degradation products.
Loss on Drying: This measures the volatile content, typically not exceeding 2.0% w/w.
Heavy Metals: Limits are set to ensure minimal presence of toxic heavy metals, often not more than 10 ppm or 20 ppm.
pH: The pH of a solution of ibandronate sodium is controlled within a specific range, usually between 4.0 and 6.0 for a 1% w/v solution.
Residual Solvents: Limits for residual solvents used during synthesis are defined by ICH guidelines (e.g., ICH Q3C), with specific ppm limits for solvents like methanol, ethanol, and isopropanol.
Microbial Enumeration Tests: For non-sterile APIs, limits for total aerobic microbial count and total yeast and mold count are specified, along with tests for specified microorganisms.

These specifications are detailed in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). Manufacturers must demonstrate compliance with these monographs through rigorous testing and quality control procedures.

What are the Primary Applications of Ibandronate Sodium?

Ibandronate sodium is primarily used in the pharmaceutical industry as an active pharmaceutical ingredient (API) for the treatment of bone disorders, most notably osteoporosis.

Primary applications include:

Treatment of Postmenopausal Osteoporosis: This is the most significant application. Ibandronate sodium helps reduce the risk of fractures by inhibiting bone resorption, thereby increasing bone mineral density. It is available in oral (monthly tablets) and intravenous (quarterly injection) formulations.
Treatment of Glucocorticoid-Induced Osteoporosis: In patients who require long-term corticosteroid therapy, ibandronate sodium can be used to prevent bone loss.
Treatment of Bone Metastases in Cancer: While other bisphosphonates are more commonly cited for this indication, ibandronate sodium may also be used in specific cancer treatment protocols to reduce skeletal-related events in patients with bone metastases.

The efficacy of ibandronate sodium is well-established, leading to its consistent demand within the global pharmaceutical market for osteoporosis management.

Key Takeaways

The global supply of ibandronate sodium is robust, with established manufacturers in Europe and India serving the pharmaceutical industry. Key patent expirations in major markets, starting in the early to mid-2010s, have led to the widespread availability of generic ibandronate sodium products. Manufacturers must adhere to stringent pharmacopoeial standards (USP, Ph. Eur., JP) for API purity, impurity profiles, and residual solvents. The primary application of ibandronate sodium is in the treatment of osteoporosis, a condition with persistent global demand.

Frequently Asked Questions

Are there any remaining patents that could impact the supply of ibandronate sodium? While core compound and early formulation patents have expired, method-of-use patents or patents for novel delivery systems could still exist and potentially influence specific market segments or future product development. A thorough freedom-to-operate analysis is recommended for any new product launch.
What is the typical lead time for sourcing ibandronate sodium API from major manufacturers? Lead times can vary significantly based on manufacturer capacity, order volume, and current market demand. Typically, for established APIs like ibandronate sodium, lead times can range from 8 to 20 weeks from order confirmation to delivery.
How do regulatory agencies ensure the quality of generic ibandronate sodium? Generic ibandronate sodium products must undergo rigorous review by regulatory agencies (e.g., FDA, EMA). This includes demonstrating bioequivalence to the reference product, maintaining stringent Good Manufacturing Practices (GMP) in API and finished product manufacturing, and meeting all pharmacopoeial specifications.
What are the main challenges in ibandronate sodium API manufacturing? Challenges include maintaining high purity levels, effectively controlling specific process-related impurities, managing solvent residues, and scaling up production to meet global demand while adhering to environmental regulations.
Can ibandronate sodium be used for conditions other than osteoporosis? While its primary indication is osteoporosis, bisphosphonates, including ibandronate sodium, are investigated and sometimes used for other conditions involving bone loss or excessive bone turnover, such as Paget's disease of bone or to prevent skeletal-related events in cancer patients, though other bisphosphonates may be more commonly prescribed for these specific uses.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from USPTO website. [2] European Patent Office. (n.d.). Espacenet - Patent Search. Retrieved from EPO website. [3] Japan Patent Office. (n.d.). J-PlatPat. Retrieved from JPO website. [4] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website. [5] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from EMA website. [6] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from USP website. [7] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from EDQM website. [8] Japanese Pharmacopoeia. (n.d.). The Japanese Pharmacopoeia. Retrieved from JP website. [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ICH website.

Suppliers and packagers for IBANDRONATE SODIUM